<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11550">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01848106</url>
  </required_header>
  <id_info>
    <org_study_id>REG1-CLIN310</org_study_id>
    <secondary_id>2013-001384-23</secondary_id>
    <nct_id>NCT01848106</nct_id>
  </id_info>
  <brief_title>A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI</brief_title>
  <acronym>Regulate</acronym>
  <official_title>A Randomized, Open-Label, Multi-Center, Active-Controlled, Parallel Group Study To Determine the Efficacy and Safety of the REG1 Anticoagulation System Compared to Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regado Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian VIGOUR Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mount Sinai School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regado Biosciences, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the efficacy of REG1 compared to bivalirudin in
      preventing periprocedural ischemic complications and major bleeding in patients undergoing
      PCI as a treatment for CAD.  Bivalirudin has been studied in patients undergoing PCI in both
      ACS (NSTEMI and unstable angina [UA]) and elective PCI. In comparison to UFH, bivalirudin
      has shown similar rates of ischemic events while demonstrating a significant reduction in
      bleeding and an improved net clinical benefit.

      Evidence from previous studies indicates that pegnivacogin represents an extremely potent,
      chemically unique anticoagulant that can be reversed by anivamersen across multiple
      populations (refer to Section 1.2.2).  The question that still remains is whether Factor IX
      (FIX) inhibition by pegnivacogin can result in fewer ischemic events than a previously
      studied agent while active control with anivamersen can preserve the benefit of reduced
      bleeding.  The purpose of this study is to evaluate REG1 in an adequately powered definitive
      study with an open-label, multi-center, active-controlled, randomized design to answer that
      question.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ischemic composite</measure>
    <time_frame>Day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary efficacy endpoint is the composite of death, nonfatal myocardial infarction, nonfatal stroke and urgent TLR through Day 3.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">13200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Bivalirudin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bivalirudin bolus and infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reg 1 (pegnivacogin/anivamersen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bolus pegnivacogin plus anivamersen active control agent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegnivacogin/anivamersen</intervention_name>
    <arm_group_label>Reg 1 (pegnivacogin/anivamersen)</arm_group_label>
    <other_name>Reg 1 Anticoagulation System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <arm_group_label>Bivalirudin</arm_group_label>
    <other_name>Angiox, Angiomax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The study population will consist of patients with CAD undergoing PCI.  Three key
             subgroups will be included

          2. Willing and able to sign an Institutional Review Board/Ethics Committee (IRB/EC)
             approved informed consent prior to any study-related activities;

          3. Male or female age 18 or greater;

          4. If female of childbearing potential, must have a negative urine or serum pregnancy
             test or be post-menopausal for at least 1 year prior to randomization.  Females of
             childbearing potential must be practicing adequate birth control to be eligible.  It
             is the Investigator's responsibility for determining whether the patient has adequate
             birth control for study participation;

          5. Subject is able and willing to comply with the protocol and all study procedures

        Exclusion Criteria:

          1. Acute ST-segment elevation myocardial infarction within 48 hours of randomization;

          2. Evidence of current clinical instability

          3. Evidence of a contraindication to anticoagulation or increased risk of bleeding

          4. Use of any investigational drug or device within 30 days of randomization or the
             planned use of an investigational drug or device through EOS (Day 30 follow-up);

          5. Use of the select antithrombotic agents

          6. Baseline hemoglobin (Hgb) &lt;9 g/dL or equivalent;

          7. Baseline estimated glomerular filtration rate (GFR) ≤ 10 mL/min/1.73m² or currently
             undergoing renal replacement therapy (hemodialysis or peritoneal dialysis);

          8. Baseline platelet count &lt;100,000/mm3;

          9. Known allergy or intolerance to aspirin, to all available ADP/P2Y12 inhibitors
             (clopidogrel, prasugrel, ticagrelor), or to bivalirudin or REG1 (or any of their
             respective components);

         10. The following planned procedures:  a. Planned staged PCI procedure within 3 days
             after randomization; b. Planned CABG or valve surgery within 30 days after
             randomization;

         11. Any other medical or psychiatric condition that in the Investigator's judgment
             precludes participation in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven L Zelenkofske, DO, FACC</last_name>
    <role>Study Director</role>
    <affiliation>Regado Biosciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A. Michael Lincoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roxana Mehran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John H Alexander, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raul P Lima, MA, MBA</last_name>
    <phone>9085802100</phone>
    <email>regulate@regadobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Black Hills Cardiovascular Research</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Drew Purdy, MD</last_name>
      <phone>605-718-4917</phone>
      <email>bhcrpurdy@regionalhealth.com</email>
    </contact>
    <investigator>
      <last_name>Drew Purdy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 4, 2013</lastchanged_date>
  <firstreceived_date>May 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Regado</keyword>
  <keyword>Reg 1</keyword>
  <keyword>bivalirudin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bivalirudin</mesh_term>
    <mesh_term>Hirudins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
